https://scholars.lib.ntu.edu.tw/handle/123456789/558494
標題: | The renoprotective potential of pentoxifylline in chronic kidney disease | 作者: | SHUEI-LIONG LIN WEN-CHIH CHIANG YUNG-MING CHEN CHUN-FU LAI TUN-JUN TSAI Hsieh B.-S. |
公開日期: | 2005 | 出版社: | Chinese Medical Association - Taipei | 卷: | 68 | 期: | 3 | 起(迄)頁: | 99-105 | 來源出版物: | Journal of the Chinese Medical Association | 摘要: | Current interventions with proven efficacy, such as glycemic and blood pressure control, dietary protein restriction, and angiotensin II blockade, slow the progression of chronic kidney disease (CKD); however, whether long-term cessation of CKD progression is possible remains unclear. Because of the pathogenetic complexity of this condition, multidrug interventions with the least adverse effects should be investigated as the next step in attempts to stop CKD progression. Pentoxifylline, a non-selective phosphodiesterase inhibitor with indiscernible toxicity, exerts potent inhibitory effects against cell proliferation, inflammation, and extracellular matrix accumulation, all of which play important roles in CKD progression. Pentoxifylline monotherapy markedly reduces proteinuria in patients with membranous nephropathy. Moreover, limited human studies have proven pentoxifylline efficacy in reducing proteinuria in patients with diabetes receiving angiotensin-converting enzyme inhibitors, and in patients with nephrotic syndrome secondary to lupus nephritis despite immunosuppressive therapy. Further clinical trials are necessary to examine whether pentoxifylline can improve renal outcomes in patients receiving interventions of proven efficacy. ? 2005 Elsevier. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-16844381073&doi=10.1016%2fS1726-4901%2809%2970228-X&partnerID=40&md5=4a9854692aa0512e9350dbc92465ebab https://scholars.lib.ntu.edu.tw/handle/123456789/558494 |
ISSN: | 1726-4901 | DOI: | 10.1016/S1726-4901(09)70228-X | SDG/關鍵字: | angiotensin 2 receptor antagonist; dipeptidyl carboxypeptidase inhibitor; immunosuppressive agent; pentoxifylline; phosphodiesterase inhibitor; pentoxifylline; phosphodiesterase inhibitor; blood pressure regulation; cell proliferation; chronic kidney disease; diabetic nephropathy; disease course; dizziness; drug efficacy; dyspepsia; extracellular matrix; gastrointestinal symptom; glucose homeostasis; human; inflammation; lupus erythematosus nephritis; membranous glomerulonephritis; monotherapy; nausea; nephrotic syndrome; nonhuman; protein restriction; proteinuria; renal protection; review; chronic kidney failure; drug effect; proteinuria; Cell Proliferation; Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Pentoxifylline; Phosphodiesterase Inhibitors; Proteinuria |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。